Hormonal
Gastrointestinal (GI) surgery is the only current treatment capable of achieving significant, long-term sustainable weight loss, primarily by altering the physiology and circulating levels of appetite-regulating gut hormones.
If you are struggling with obesity and other methods haven't provided lasting results, GI surgery is currently the only treatment proven to offer significant, long-term weight loss. This works by changing your gut hormones (like GLP-1 and PYY) to naturally reduce appetite. While surgery has risks and costs, it serves as the benchmark for what hormonal therapies aim to achieve safely.
Among current treatments, however, gastrointestinal (GI) surgery remains the only approach capable of achieving significant weight loss results with long-term sustainability.
Why this rating
The paper cites multiple studies and establishes a consensus view on the hormonal mechanisms post-surgery.
Source
Appetite regulation and weight control: the role of gut hormones
Ben D. Perry et al. · Nutrition and Diabetes · 2012
DOI 10.1038/nutd.2011.21
More from this paper
- Obesity is associated with 'leptin resistance,' where high circulating levels of leptin fail to produce expected anorexigenic effects due to receptor over-stimulation and impaired transport across the blood-brain barrier.Good
- Gut hormones including GLP-1, PYY, and OXM are anorexigenic (appetite-suppressing) and are released in higher amounts after GI surgery, contributing to weight loss, whereas Ghrelin (orexigenic) levels are often reduced.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →